196
Participants
Start Date
August 31, 2022
Primary Completion Date
June 26, 2024
Study Completion Date
December 31, 2028
Lutetium[177Lu] Oxodotreotide Injection
Four administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
Octreotide LAR
60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.
Chinese PLA General Hospital, Beijing
The first hospital of Jilin University, Changchun
Fudan University Shanghai Cancer Center, Shanghai
Zhongshan Hospital, Fudan University, Shanghai
Nanjing First Hospital, Nanjing
Qilu Hospital of Shandong University, Jinan
Tianjin Medical University Cancer Institute & Hospital, Tianjin
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
The First Afilliated Hospital of Fujian Medical University, Fuzhou
The First Affiliated Hospital of Xiamen University, Xiamen
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan
Henan Provincial People's Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou
The First Affiliated Hospital of Jinan University, Guangzhou
West China Hospital of Sichuan University, Chengdu
Mianyang Central Hospital, Mianyang
Affiliated Hospital of Southwest Medical University, Luzhou
The First Affiliated Hospital of AFMU, Xi'an
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
The First Affiliated Hospital of Shanxi Medical University, Taiyuan
Sinotau Pharmaceutical Group
INDUSTRY